ID: ALA4865459

Max Phase: Preclinical

Molecular Formula: C21H16N2O2

Molecular Weight: 328.37

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  O=C1CCCC2=C1C(c1ccncc1)C1=C(N2)c2ccccc2C1=O

Standard InChI:  InChI=1S/C21H16N2O2/c24-16-7-3-6-15-18(16)17(12-8-10-22-11-9-12)19-20(23-15)13-4-1-2-5-14(13)21(19)25/h1-2,4-5,8-11,17,23H,3,6-7H2

Standard InChI Key:  NETMGMZZMXIDFJ-UHFFFAOYSA-N

Associated Targets(Human)

Probable G-protein coupled receptor 174 370 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 328.37Molecular Weight (Monoisotopic): 328.1212AlogP: 3.38#Rotatable Bonds: 1
Polar Surface Area: 59.06Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 5.03CX LogP: 1.69CX LogD: 1.69
Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.87Np Likeness Score: -0.65

References

1.  (2020)  Inhibitors of GPR174 and Uses Thereof, 
2.  (2020)  Methods and Compositions for Treating Cancer, 

Source